Myelofibrosis Clinical Trials

90 recruitingLast updated: June 17, 2026

There are 90 actively recruiting myelofibrosis clinical trials across 48 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1. Top locations include New York, New York, United States, Houston, Texas, United States, Seattle, Washington, United States. Updated daily from ClinicalTrials.gov.


Myelofibrosis Trials at a Glance

90 actively recruiting trials for myelofibrosis are listed on ClinicalTrialsFinder across 6 cities in 48 countries. The largest study group is Phase 2 with 35 trials, with the heaviest enrollment activity in New York, Houston, and Seattle. Lead sponsors running myelofibrosis studies include M.D. Anderson Cancer Center, Masonic Cancer Center, University of Minnesota, and Memorial Sloan Kettering Cancer Center.

Browse myelofibrosis trials by phase

Treatments under study

About Myelofibrosis Clinical Trials

Looking for clinical trials for Myelofibrosis? There are currently 51 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myelofibrosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myelofibrosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 90 trials

Recruiting
Phase 3

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals460 enrolled13 locationsNCT07357727
Recruiting
Phase 1

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Novartis Pharmaceuticals6 enrolled7 locationsNCT07340138
Recruiting
Phase 1

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Primary myelofibrosis (PMF)Post-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more
Prelude Therapeutics100 enrolled5 locationsNCT07469891
Recruiting

Research Platform Myelofibrosis and Anemia

MyelofibrosisAnemiaPrimary Myelofibrosis+4 more
iOMEDICO AG200 enrolled1 locationNCT06976918
Recruiting
Phase 1

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

MyelofibrosisSecondary AML
Aspera Biomedicines, Inc.28 enrolled1 locationNCT07250646
Recruiting
Phase 1

AlloHCT With PegINFa for Myelofibrosis

Myelofibrosis
University of Utah18 enrolled1 locationNCT05535764
Recruiting
Early Phase 1

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+4 more
Omar Aljitawi24 enrolled1 locationNCT03964506
Recruiting
Phase 3

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Beta-ThalassemiaMyelodysplastic Syndromes (MDS)Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Celgene665 enrolled143 locationsNCT04064060
Recruiting
Phase 1Phase 2

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-Essential Thrombocytosis Myelofibrosis
M.D. Anderson Cancer Center33 enrolled1 locationNCT06327100
Recruiting
Phase 1

Therapeutic RSK1 Targeting in Myelofibrosis

Myelofibrosis
Washington University School of Medicine18 enrolled1 locationNCT07379125
Recruiting
Phase 2

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Myelodysplastic/Myeloproliferative NeoplasmPolycythemia VeraPrimary Myelofibrosis+5 more
National Cancer Institute (NCI)62 enrolled31 locationsNCT06661915
Recruiting
Phase 1Phase 2

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Myelodysplastic SyndromesMyelofibrosisAnemia+4 more
Disc Medicine, Inc150 enrolled25 locationsNCT05320198
Recruiting
Phase 1

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more
Ajax Therapeutics, Inc.76 enrolled21 locationsNCT06343805
Recruiting

Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm

Primary myelofibrosis (PMF)Essential Thrombocythemia, ETMyeloproliferative Neoplasm (MPN)+1 more
Université Catholique de Louvain150 enrolled1 locationNCT07590986
Recruiting
Phase 2

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Myelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Icahn School of Medicine at Mount Sinai10 enrolled9 locationsNCT05835466
Recruiting
Phase 1Phase 2

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Myelofibrosis
Sumitomo Pharma America, Inc.240 enrolled84 locationsNCT04176198
Recruiting
Early Phase 1

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Myelofibrosis (MF)
University of Kansas Medical Center20 enrolled1 locationNCT06414681
Recruiting
Phase 1

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Acute Myeloid LeukemiaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+10 more
Newave Pharmaceutical Inc100 enrolled8 locationsNCT04771572
Recruiting
Phase 2

Methods of T Cell Depletion Trial (MoTD)

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+6 more
University of Birmingham400 enrolled17 locationsNCT04888741
Recruiting
Phase 1Phase 2

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

MyelofibrosisMyelofibrosis; Anemia
University of California, Irvine10 enrolled1 locationNCT07281781